Biomedtech News

ABX464 shows excellent long-term efficacy data in Abivax's phase 2B maintenance trial in ulcerative colitis

October 19, 2021

Impressive clinical remission in 58.4% (ITT) of 101 patients after 48 weeks of once-daily oral 50mg ABX464, showing both maintained as well as further improved efficacy
Favorable safety and tolerability profile continues to support ABX464 chronic use potential
Launch of global phase 3 program with ABX464 in ulcerative colitis in preparation, with end-of-Phase-2 US FDA meeting in Q4 2021 and EMA Scientific Advice in early Q1 2022
Abivax’s late-breaking abstract presentation and Live Industry Symposium at UEG Week Virtual 2021 now publicly available

ALSO TO BE DISCOVERED

September 24, 2021

Abivax presents first-half 2021 financial results and operations update

September 15, 2021

Abivax provides an update on the ABX464 clinical data and development strategy in ulcerative colitis

September 8, 2021

Merck KGaA entrusts secretive startup with a mid-stage cancer drug targeting master signaling pathway

September 8, 2021

Diaccurate Acquires Clinical Stage Sole-in-Class Targeted Cancer Therapy from Merck

August 23, 2021

Could HIV be cured by tackling ‘bumpy’ CD4 cells? France’s Diaccurate wants to find out

August 18, 2021

Abivax receives approval for ABX464 phase 1 study in Japanese subjects for subsequent inclusion of Japan into the global phase 3 program in ulcerative colitis

July 19, 2021

Carmat sells its artificial heart for the first time in Italy

July 8, 2021

Diaccurate introduces its world-leading scientific advisory board

June 10, 2021

AFFLUENT MEDICAL announces the success of its initial public offering on the Euronext Paris regulated market

May 25, 2021

Abivax announces excellent results